

# DAVY DISCOVERY FUND

FROM  
NEW IRELAND

## Q4 2018 UPDATE

This fund is provided by New Ireland Assurance plc and is managed by Davy Asset Management.

PERFORMANCE	1 MONTH (%)	Q4 2018 (%)	1 YEAR (%)	3 YEARS P.A. (%)	5 YEARS P.A. (%)
DAVY DISCOVERY FUND* (GROSS OF FEES)	-9.3	-17.4	-9.1	5.1	8.9
MSCI WORLD SMALL AND MID-CAP INDEX (TOTAL RETURN)	-9.5	-15.5	-8.9	3.9	8.3

Source: New Ireland (\*Discovery Fund Series 6, performance is quoted gross of taxation and fund management charge) and Bloomberg as at 31st December 2018. The fund management charge and product charges will vary depending on the terms and conditions of your policy.

### FUND OVERVIEW

The investment aim of the **Davy Discovery Fund** (the 'Fund') is to achieve long-term capital growth by investing in shares of small and medium sized companies on a global basis. These companies demonstrate growth potential and represent attractive investment opportunities. Investing during the early stage of a company's life cycle can lead to higher than average investment returns.

### FUND PERFORMANCE

The Fund declined by -17.4% versus -15.5% for its benchmark the MSCI World SMID over the final quarter of 2018, as Stock Selection, Asset Allocation and Currency made negative contributions to performance. The strong rebound in Value relative to Growth in the latter months of 2018 meant the Discovery Fund performed broadly in-line with its benchmark for the year. The Fund remains ahead of its benchmark over the longer term of 3Y and 5Y by 1.2% and 0.6% respectively.

The final quarter of 2018 began and ended with markets focused on sentiment not fundamentals. The third quarter earnings seasons was broadly positive for companies, with over 60% of stocks in the Index beating expectations. Nonetheless, the market is concerned about issues such as Brexit and President Trump's "tariff tantrum" with China. These, in combination with lower global GDP growth forecasts from the IMF and higher US interest rates, have caused stocks to deviate from their fundamental valuations.

The Information Technology sector was once again the top performing sector in the Fund for the quarter with Chinese travel software provider **Travelsky** and **Cadence Design Systems** outperforming the broader market. Despite the markets concerns over the strength of the Chinese economy and the effect of trade tariffs with the US, air traffic in and out of China is strong. Considering, Travelsky's monopoly position in its domestic market, EPS growth which is faster than its global peers, and anticipated expansion in operating margins in 2019, we expect the stock to re-rate over the course of the year. Similarly, Cadence whose growth prospects are related to long term secular trends and greater economies of scale by moving part of its product portfolio to the cloud. Over the course of 2018, earnings expectations for that year and 2019 were revised upwards by c.20%. Given the positive secular outlook for the firm earnings for 2019 which are expected to grow by c. 7%, are likely to be revised upwards as the year progresses. The improved outlook is tied to better execution in the IP segment and robust demand for emulation software.

On the downside, high quality stocks such as **Cognex** have suffered from the deceleration of the growth rate of the automation sector. History suggests these downturns tend to be brief and shallow as this is a long-term secular trend. The stock is trading towards the lower end of its historic trading range having de-rated but given the positive outlook for this sector and its oligopolistic position we have used this weakness to top-up our position. Importantly, its gross and operating margins are more like those of a software company than an industrial and it is debt free, so well positioned to benefit from any rebound in demand as the year develops.

### SAMPLE PORTFOLIO TRANSACTIONS

The Fund made three disposals and one purchase over the quarter. **Idexx**, **LKQ** and **Azimut** were sold while Medidata Solutions was bought. We invested in **Medidata** as it's a cloud based electronic data capture and data management platform used in clinical trials. This system is being used to replace traditional paper-based clinical data management as increased regulation and complexity is driving the need for more efficient paperless framework. This means its revenues model has a high degree of visibility as 85% of revenues are subscription based with the remainder coming from professional services. It estimates there are c.150,000+ registered clinical trials underway globally and only 10% of these use dedicated software.

We took the opportunity to exit Idexx Laboratories Inc having made a c.70% return over the 18 months the Fund held the stock. It's a market leader for animal healthcare innovation, developing diagnostic, detection and information systems used in the veterinary (60% market share), livestock, water testing and dairy markets. Over 86% of revenues are from companion animals with livestock contributing 8% with water testing the remainder. This results in a very stable and visible revenue stream. Over the last 12 months we have been gradually exiting our position in LKQ.

This company specialises in distributing reclaimed vehicle parts which cost 20-40% less than comparable new OEM parts. Although LKQ is high-cash generative, it is highly levered as it grows by acquisition and a rising interest rate environment is likely to be more challenging for its business model.

Markets for most of 2018 were surprisingly robust despite the rapidly evolving political environment, which caused them to fluctuate. The sell-off in the final quarter highlights once again the importance of investing in high quality businesses. Corporate earnings are expected to be positive for 4Q18 due to the positive effects of lower corporate taxes. Importantly for investors, equities are the cheapest they've been since 2013 and many of these negative headlines are likely to soften in 2019.

CALENDAR YEAR PERFORMANCE	2018 (%)	2017 (%)	2016 (%)	2015 (%)	2014 (%)
Davy Discovery Fund* (Gross of Fees)	-9.1	15.3	10.6	14.2	15.9
MSCI World Small and Mid-Cap Index (Total Return)	-13.2	23.5	10.4	0.4	4.1
Travelsky Technology	-13.4	45.4	29.4	54.3	12.3
Cadence Design Systems	4.0	65.8	21.2	9.7	35.3
Cognex Corp	-36.5	92.9	89.6	-17.9	8.3
Medidata	6.4	27.6	0.8	3.2	-21.1
LKQ Corp	-41.7	32.7	3.4	5.4	-14.5
Idexx Laboratories	19.0	33.4	60.8	-1.6	39.4

Source: New Ireland (\*Discovery Fund Series 6, performance is quoted gross of taxation and fund management charge), MSCI and Bloomberg as at 31st December 2018. The fund management charge and product charges will vary depending on the terms and conditions of your policy. Performance is quoted in local currency unless otherwise stated.

**WARNING: Past performance is not a reliable guide to future performance.**

This report does not constitute an offer for the purchase or sale of any financial instrument, trading strategy, product or service. No one receiving this report should treat any of its contents as constituting advice or a personal recommendation. It does not take into account the investment objectives or financial situation of any particular person. All investments involve a degree of risk. Equities may involve a high degree of risk and may not be suitable for all investors. Government bonds and cash deposits, although considered the safest assets, are not devoid of risk (e.g. inflation risk, credit risk, currency risk, etc.). There are different reasons why an investor would choose to invest in a particular asset class and each investor must consider the inherent risks therein based on his/her own personal circumstances. The value of these investments can rise as well as fall. There is no guarantee that the investments discussed will achieve results comparable to those achieved in the past or that capital will be returned to investors. Neither past experience nor the current situation are necessarily accurate guides to the future.

MSCI Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an 'as is' basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

Davy Asset Management Limited, trading as Davy Asset Management, is regulated by the Central Bank of Ireland. In the UK, Davy Asset Management is authorised by the Central Bank of Ireland and authorised and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our authorisation and regulation by the Financial Conduct Authority are available from us on request. No part of this document is to be reproduced without our written permission. This document has been prepared and issued by Davy Asset Management on the basis of publicly available information, internally developed data and other sources believed to be reliable. The information contained herein does not purport to be comprehensive and is strictly for information purposes only. It does not constitute an offer or an invitation to invest. No party should treat any of the contents herein as advice in relation to any investment. While all reasonable care has been given to the preparation of this information, no warranties or representation expressed or implied are given or liability accepted by Davy Asset Management or its affiliates or any directors or employees in relation to the accuracy fairness or completeness of the information contained herein. Any opinion expressed (including estimates and forecasts) may be subject to change without notice. We or any of our connected or affiliated companies or their employees may have a position in, or may have provided within the last twelve months, significant advice or investment services in relation to any of the securities or related investments referred to in this document.